RESEARCH MONOGRAPH · KDC-MN-312

DMAE

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

57/100

Old-school choline analog that punches above its weight as a research tool, below it as a nootropic

DMAE is one of those compounds that's been kicking around since the Riker labs work in the late 50s and somehow still hasn't been pinned down mechanistically. The popular story is that it's a choline precursor that gets methylated to choline and feeds into acetylcholine synthesis, but the actual evidence for that pathway in mammalian brain is honestly pretty thin. The methylation step (DMAE to choline via PEMT-like enzymes) isn't well characterized in CNS tissue at all.

What it does do, demonstrably, is cross the blood-brain barrier and accumulate in neuronal membranes. There's interesting older work on it stabilizing phospholipid membranes against peroxidation, and the Schloss/Hochschild lifespan papers in rodents showed real effects, though nobody's replicated them cleanly at modern standards. The Deanol era in pediatric psychiatry (60s-70s, used for ADHD-like presentations) generated a small RCT literature thats mostly forgotten now, partly because the effect sizes were modest and partly because methylphenidate ate that market.

Heres the thing we find interesting: DMAE shows up in lipofuscin clearance studies. The pigment that accumulates in aging neurons. Nagy and colleagues had some decent work on this in the 80s. Whether thats meaningful for anything outside cell culture is anyones guess but it's the angle that actually keeps the molecule on our radar.

Sourcing is easy. It's a small tertiary amine, usually sold as the bitartrate salt, stable, cheap, NMR-trivial to verify. Vendor variability is basically a non-issue at the gram scale, you're mostly paying for handling. Where people get burned is buying the cosmetic-grade stuff and assuming it's research grade, those are very different QC pipelines.

What we don't like is the supplement-industry framing of DMAE as a 'mind-power' compound. The clinical signal for cognitive enhancement in healthy adults is weak to nonexistent, and the headache/jaw-tension reports at higher exposures are real and replicable. If you're working on aging-related membrane biology, lipofuscin, or PEMT pathway stuff, it has a place. As a general cholinergic tool, alpha-GPC and citicoline are better characterized and you'd rather use those.

Worth having on the shelf for specific aging-biology questions. Not a workhorse.

Evidence: 40
Mechanism: 35
Reliability: 45
Safety: 70
Sourcing: 88
Value: 75
Signal: 50
Staying power: 55

Plain-language summary Intrigue 38 / 100

DMAE (2-(dimethylamino)ethanol) is a small molecule structurally related to choline that crosses the blood-brain barrier easily. The hypothesis has long been that it acts as a precursor to acetylcholine and phosphatidylcholine in the brain, but the evidence has been mixed and DMAE may actually be more of a methyl donor than a true cholinergic precursor. Its predecessor, deanol, was sold for ADHD until pulled from the US market in the 1980s for inadequate efficacy data. It survives in nootropic supplements and in topical skin-firming creams (the cosmetic mechanism is poorly understood). Reports of headaches and worsened depression in some users. Long-running compound with weak underlying evidence. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Quaternary amine choline precursor

2-(dimethylamino)ethanol; a quaternary amine alcohol that crosses the blood-brain barrier; used as a cholinergic precursor and skin-firming agent.

Abstract

DMAE (2-(dimethylamino)ethanol; CAS 108-01-0; molecular formula C4H11NO; molecular weight 89.14) is a small quaternary amine alcohol structurally related to choline. The compound crosses the blood-brain barrier readily and is hypothesized to serve as a precursor to phosphatidylcholine and acetylcholine in cholinergic neurons; supporting evidence is mixed. Used historically for ADHD (precursor compound deanol, removed from US market 1980s for inadequate efficacy data) and as a nootropic supplement. The cosmetic application is in topical skin-firming creams marketed for facial muscle tone. Plasma half-life is approximately 1 to 2 hours; oral bioavailability is high. The active form centrophenoxine (a DMAE-pCPA ester) has more pronounced cognitive activity and is covered separately. Used as a small-molecule choline precursor in research.

Mechanism of action

Choline analog and possible cholinergic precursor; crosses BBB with high efficiency. Mechanism in cosmetics is incompletely characterized.

Reported research dose ranges

Supplement 100 to 600 mg in the published literature; topical 1 to 3 percent solution.

References

Pfeiffer CC, et al. Stimulant effect of 2-dimethyl-1-aminoethanol. Science 1957.
Dimpfel W, et al. Effects of DMAE on EEG and behavior. Neurosci Biobehav Rev 2003.
Uhoda I, et al. Topical DMAE for skin firming: clinical evidence review. Skin Res Technol 2002.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-312

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

DMAE

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs